Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03824691
Title hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study" (ARCADIA)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

urethra transitional cell carcinoma

ureter transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma


Cabozantinib + Durvalumab

Age Groups: senior | adult
Covered Countries ITA

No variant requirements are available.